News Image

IN8bio Reports Fourth Quarter and Full-Year 2024 Financial Results and Recent Business Highlights

Provided By GlobeNewswire

Last update: Mar 13, 2025

NEW YORK, March 13, 2025 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta T cell therapies, today reported financial results and business highlights for the fourth quarter and full-year ended December 31, 2024.

Read more at globenewswire.com

IN8BIO INC

NASDAQ:INAB (8/1/2025, 10:56:58 AM)

2.15

+0.02 (+0.94%)



Find more stocks in the Stock Screener

Follow ChartMill for more